Reclassification of variants of uncertain significance in BRCA1/2 impact clinical management, health outcomes, and healthcare costs, raising questions about cost-effectiveness and optimal timing of reinterpretation. This study evaluated cost-effectiveness of BRCA1/2 variant reclassification strategies and how timing and duration influence outcomes.